You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Sodium-Glucose Cotransporter-2 (SGLT2) inhibitor

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Cystinuria Trial in San Francisco (Dapagliflozin)

Not yet recruiting
  • Cystinuria
  • San Francisco, California
    University of California, San Francisco
Sep 13, 2022

Sodium Glucose Cotransporter 2 Inhibitiors on Left Ventricular

Not yet recruiting
  • SGLT2 Inhibitiors Remodeling Effect
  • Chronic Heart Disease
  • Sodium-glucose cotransporter 2 inhibitor
  • (no location specified)
Nov 14, 2023

Diabetes, Type 2, Endothelial Dysfunction Trial in Boston (Dapagliflozin, Placebo)

Recruiting
  • Diabetes Mellitus, Type 2
  • Endothelial Dysfunction
  • Boston, Massachusetts
    BU School of Medicine Evans 748
Jun 1, 2022

Diabetes, Cellular Senescence, Sodium-Glucose Transporter 2 Inhibitors Trial in Seoul (SGLT2 inhibitor, Glimepiride)

Not yet recruiting
  • Diabetes Mellitus
  • +2 more
  • Seoul, Korea, Republic of
    Yonsei University College of Medicine
Aug 1, 2023

SGLT2 Inhibition in Heart Failure

Recruiting
  • Heart Failure
  • Sodium-glucose cotransporter 2 inhibitor
  • Belfast, United Kingdom
    Belfast Health and Social Care Trust
Nov 15, 2023

MDD Trial in New York (Empagliflozin)

Not yet recruiting
  • Major Depressive Disorder
  • New York, New York
    NYU Langone Health
Feb 24, 2023

Sodium-glucose Cotransporter 2 Inhibitors+Sacubitril/Valsartan

Recruiting
  • Heart Failure
  • +2 more
  • SGLT2 inhibitor
  • Roma, RM, Italy
    Fondazione Policlinico Universitario A. Gemelli IRCSS
Jun 28, 2023

Fatty Liver, Nonalcoholic Trial (SGLT2 inhibitor)

Not yet recruiting
  • Fatty Liver, Nonalcoholic
  • SGLT2 inhibitor
  • (no location specified)
Oct 31, 2023

Tricuspid Regurgitation Trial in Seoul (Dapagliflozin Propanediol Hydrate 12.3 mg)

Recruiting
  • Tricuspid Regurgitation
  • Dapagliflozin Propanediol Hydrate 12.3 mg
  • Seoul, Korea, Republic of
    Samsung Medical Center
Jan 9, 2023

Fatty Liver Disease Trial in Tainan (Canagliflozin 100mg)

Completed
  • Fatty Liver Disease
  • Canagliflozin 100mg
  • Tainan, Taiwan
    National Cheng Kung University Hospital
Feb 28, 2023

Renal Insufficiency, Chronic Trial in Mansoura, Tanta (Metformin, Empagliflozin, Standard therapy)

Recruiting
  • Renal Insufficiency, Chronic
  • Mansoura, Dakahlia Governorate, Egypt
  • +1 more
May 12, 2022

Heart Failure With Reduced Ejection Fraction Trial in Porto (Sacubitril-valsartan, SGLT2 inhibitor)

Recruiting
  • Heart Failure With Reduced Ejection Fraction
  • Porto, Portugal
  • +3 more
Aug 9, 2023

SGLT-2 Inhibitors in the Treatment of Ascites

Recruiting
  • Ascites Hepatic
  • +2 more
  • SGLT2 inhibitor
  • Palermo, Italy
  • +1 more
Aug 11, 2023

Sleep Apnea Trial in New Haven, Cleveland (Ertugliflozin 15 mg, Placebo)

Not yet recruiting
  • Sleep Apnea
  • Ertugliflozin 15 mg
  • Placebo
  • New Haven, Connecticut
  • +1 more
Jan 24, 2023

Acute Kidney Injury, Cardiac Surgery, Sodium-Glucose Transporter 2 Inhibitor Trial in Netherlands (Dapagliflozin 10 MG Oral

Not yet recruiting
  • Acute Kidney Injury
  • +2 more
  • Dapagliflozin 10 MG Oral Tablet [Farxiga]
  • Placebo
  • Amsterdam, Netherlands
  • +5 more
Oct 18, 2022

Acute Kidney Injury, Kidney Failure, Sodium Glucose Cotransporter-2 Inhibitors Trial in Newtown (SGLT2 inhibitor or matched )

Not yet recruiting
  • Acute Kidney Injury
  • +2 more
  • SGLT2 inhibitor or matched placebo
  • Newtown, New South Wales, Australia
    The George Institute for Global Health
Jul 19, 2022

Cardiorenal Syndrome Trial in New Haven (Dapagliflozin)

Not yet recruiting
  • Cardiorenal Syndrome
  • New Haven, Connecticut
    Yale New Haven Hospital
Oct 26, 2023

Empagliflozin, Other SGLT-2 Inhibitors, or DPP-4 Inhibitors in

Completed
  • Diabetes Mellitus, Type 2
  • Subjects treated with Empagliflozin or any Sodium-glucose cotransporter-2 (SGLT-2) inhibitor
  • Subjects treated with Dipeptidyl peptidase-4 (DPP-4) inhibitor
  • Gentofte, Denmark
  • +12 more
Jan 18, 2022

Cystinuria Trial in San Francisco (Dapagliflozin)

Recruiting
  • Cystinuria
  • San Francisco, California
    University of California, San Francisco
Oct 4, 2022

(NIS) on Sodium-glucose Co-transporter-2 Inhibitors Use in

Not yet recruiting
  • Diabetes Mellitus, Type 2
  • Sodium/glucose cotransporter-2 inhibitors (SGLT2i)
  • (no location specified)
May 22, 2023

IgA Nephropathy, Immunoglobulin A Nephropathy Trial (Atrasentan, Placebo)

Not yet recruiting
  • IgA Nephropathy
  • Immunoglobulin A Nephropathy
  • (no location specified)
Apr 27, 2023

Heart Failure Trial in Denmark (Digital letter)

Recruiting
  • Heart Failure
  • Digital letter
  • Copenhagen, Denmark
  • +4 more
Jun 5, 2023

Diabetes, Cardiovascular Diseases Trial in Singapore (Renin-angiotensin-aldosterone system inhibitors, Beta blocker, SGLT2

Recruiting
  • Diabetes Mellitus
  • Cardiovascular Diseases
  • Renin-angiotensin-aldosterone system inhibitors
  • +2 more
  • Singapore, Singapore
    Singapore General Hospital (SGH)
Apr 28, 2021

Transthyretin Amyloid Cardiomyopathy Trial in New York (Empagliflozin)

Recruiting
  • Transthyretin Amyloid Cardiomyopathy
  • New York, New York
    Columbia University Irving Medical Center / NewYork-Presbyterian
Mar 15, 2022

Atrial Fibrillation Trial (Sodium Glucose Co-transporter 2 (SGLT2) Inhibitor, Rhythm control and anticoagulation)

Not yet recruiting
  • Atrial Fibrillation
  • Sodium Glucose Co-transporter 2 (SGLT2) Inhibitor
  • Rhythm control and anticoagulation
  • (no location specified)
Aug 14, 2023